Work

Using Second-Generation Anti-Obesity Medications

Year: 2024

Type: article

Abstract: Second-generation anti-obesity medications are more effective than their first-generation predecessors, resulting in an average weight loss of 15% when combined with lifestyle modifications. This article examines the efficacy and therapeutic implications of the three currently approved second-generation medications: setmelanotide for individuals with monogenic forms of obesity, semaglutide 2.4 mg, and tirzepatide. Particular emphasis is placed on the concurrent treatment of obesity and type 2 diabetes with semaglutide 2.4 mg and tirzepatide.

Source: Diabetes Spectrum

DOI: 10.2337/dsi24-0002

Authors: Sarah H. Schmitz, Louis J. Aronne

Institutions: NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill Cornell Medical Center

Language: English

Topic: Pharmacology and Obesity Treatment

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4404401528